Business Context and Reporting Period
This Form 8-K Current Report was filed by Capricor Therapeutics, Inc. on February 22, 2016. The filing addresses Item 5.02 regarding the appointment of a new Chief Financial Officer and the departure of the previous principal financial officer.
Key Financial Metrics
The filing text does not provide revenue, profit, cash flow, margins, debt, or liquidity metrics. This report focuses exclusively on executive personnel changes and compensation arrangements.
Material Changes
- Appointment of CFO: Leland J. Gershell, M.D., Ph.D., was appointed as Chief Financial Officer of Capricor, Inc. (a wholly-owned subsidiary) and the Company's principal financial officer effective February 22, 2016.
- Departure of Principal Financial Officer: Anthony Bergmann ceased serving as the Company's principal financial officer effective February 22, 2016. He will continue as Vice President of Finance and principal accounting officer.
- Compensation Structure: Dr. Gershell's initial base salary is set at $250,000 per year. He is eligible for bonuses, stock options, and standard employee benefits.
- Equity Grant: Subject to Board approval, Dr. Gershell will receive an option to purchase 166,500 shares of common stock. Vesting begins 25% on the first anniversary of the grant month, with the remainder vesting monthly at a rate of 1/36 thereafter.
Guidance, Outlook, and Risks
The filing contains no financial guidance, market outlook, or discussion of operational risks. The only noted contingency is that the stock option grant is subject to approval by the Company's Board of Directors. The Employment Agreement is "at-will" and may be terminated by either party with or without cause.
Investor Verification Checklist
- Verify the Board of Directors' approval of the 166,500 share stock option grant.
- Review the full text of the Employment Agreement in the upcoming Form 10-K for the year ended December 31, 2015.
- Confirm the transition of financial reporting responsibilities from Anthony Bergmann to Leland J. Gershell.
- Monitor future filings for details on any additional bonus or stock option grants determined by the Compensation Committee.